Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids

A randomized controlled trial

Michele Meschia, Fiorenza Bruschi, Maurizio Soma, Fabio Amicarelli, Rodolfo Paoletti, Piergiorgio Crosignani

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: Our purpose was to compare the effect of oral and transdermal hormone replacement therapy on lipoprotein(a) and other plasma lipids in healthy postmenopausal women. Design: A total of 120 postmenopausal women were enrolled in a prospective randomized controlled study, and allocated either to transdermal 17β-estradiol (50 μg/day) or to oral conjugated estrogen (0.625 mg/day). Forty-one age-matched women were used as the reference group. Plasma lipids and lipoproteins were determined every 3 months and differences were sought by statistical analysis. Results: Plasma lipoprotein(a) dropped after 3 months of treatment either with transdermal estradiol (p <0.01) or oral estrogen (p <0.01). Lipoprotein(a) was reduced by 12% and 22%, respectively. No further decreases were seen later on. Plasma total and low-density lipoprotein (LDL) cholesterol concentrations were decreased significantly with both treatments after 3 months of therapy. No difference was seen in the lowering effect on lipoprotein(a), LDL and total cholesterol concentrations between regimens. Plasma high-density lipoprotein (HDL) cholesterol and triglyceride concentrations increased throughout the study only in patients treated with oral estrogen. Conclusions: These data demonstrate that hormone replacement therapy reduces the concentration of lipoprotein(a) when given both orally and transdermally. The lowering effect is achieved quickly because the maximal effect is observed after 3 months of therapy.

Original languageEnglish
Pages (from-to)157-162
Number of pages6
JournalMenopause
Volume5
Issue number3
Publication statusPublished - 1998

Fingerprint

Lipid A
Lipoprotein(a)
Hormone Replacement Therapy
Lipoproteins
Randomized Controlled Trials
LDL Cholesterol
Estradiol
Estrogens
Lipids
Conjugated (USP) Estrogens
Therapeutics
HDL Cholesterol

Keywords

  • Estrogen
  • HRT
  • Lipids
  • Lipoprotein(a)

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Meschia, M., Bruschi, F., Soma, M., Amicarelli, F., Paoletti, R., & Crosignani, P. (1998). Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: A randomized controlled trial. Menopause, 5(3), 157-162.

Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids : A randomized controlled trial. / Meschia, Michele; Bruschi, Fiorenza; Soma, Maurizio; Amicarelli, Fabio; Paoletti, Rodolfo; Crosignani, Piergiorgio.

In: Menopause, Vol. 5, No. 3, 1998, p. 157-162.

Research output: Contribution to journalArticle

Meschia, M, Bruschi, F, Soma, M, Amicarelli, F, Paoletti, R & Crosignani, P 1998, 'Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: A randomized controlled trial', Menopause, vol. 5, no. 3, pp. 157-162.
Meschia M, Bruschi F, Soma M, Amicarelli F, Paoletti R, Crosignani P. Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: A randomized controlled trial. Menopause. 1998;5(3):157-162.
Meschia, Michele ; Bruschi, Fiorenza ; Soma, Maurizio ; Amicarelli, Fabio ; Paoletti, Rodolfo ; Crosignani, Piergiorgio. / Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids : A randomized controlled trial. In: Menopause. 1998 ; Vol. 5, No. 3. pp. 157-162.
@article{101cac24c6474e838ad1e68959fb990d,
title = "Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: A randomized controlled trial",
abstract = "Objective: Our purpose was to compare the effect of oral and transdermal hormone replacement therapy on lipoprotein(a) and other plasma lipids in healthy postmenopausal women. Design: A total of 120 postmenopausal women were enrolled in a prospective randomized controlled study, and allocated either to transdermal 17β-estradiol (50 μg/day) or to oral conjugated estrogen (0.625 mg/day). Forty-one age-matched women were used as the reference group. Plasma lipids and lipoproteins were determined every 3 months and differences were sought by statistical analysis. Results: Plasma lipoprotein(a) dropped after 3 months of treatment either with transdermal estradiol (p <0.01) or oral estrogen (p <0.01). Lipoprotein(a) was reduced by 12{\%} and 22{\%}, respectively. No further decreases were seen later on. Plasma total and low-density lipoprotein (LDL) cholesterol concentrations were decreased significantly with both treatments after 3 months of therapy. No difference was seen in the lowering effect on lipoprotein(a), LDL and total cholesterol concentrations between regimens. Plasma high-density lipoprotein (HDL) cholesterol and triglyceride concentrations increased throughout the study only in patients treated with oral estrogen. Conclusions: These data demonstrate that hormone replacement therapy reduces the concentration of lipoprotein(a) when given both orally and transdermally. The lowering effect is achieved quickly because the maximal effect is observed after 3 months of therapy.",
keywords = "Estrogen, HRT, Lipids, Lipoprotein(a)",
author = "Michele Meschia and Fiorenza Bruschi and Maurizio Soma and Fabio Amicarelli and Rodolfo Paoletti and Piergiorgio Crosignani",
year = "1998",
language = "English",
volume = "5",
pages = "157--162",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids

T2 - A randomized controlled trial

AU - Meschia, Michele

AU - Bruschi, Fiorenza

AU - Soma, Maurizio

AU - Amicarelli, Fabio

AU - Paoletti, Rodolfo

AU - Crosignani, Piergiorgio

PY - 1998

Y1 - 1998

N2 - Objective: Our purpose was to compare the effect of oral and transdermal hormone replacement therapy on lipoprotein(a) and other plasma lipids in healthy postmenopausal women. Design: A total of 120 postmenopausal women were enrolled in a prospective randomized controlled study, and allocated either to transdermal 17β-estradiol (50 μg/day) or to oral conjugated estrogen (0.625 mg/day). Forty-one age-matched women were used as the reference group. Plasma lipids and lipoproteins were determined every 3 months and differences were sought by statistical analysis. Results: Plasma lipoprotein(a) dropped after 3 months of treatment either with transdermal estradiol (p <0.01) or oral estrogen (p <0.01). Lipoprotein(a) was reduced by 12% and 22%, respectively. No further decreases were seen later on. Plasma total and low-density lipoprotein (LDL) cholesterol concentrations were decreased significantly with both treatments after 3 months of therapy. No difference was seen in the lowering effect on lipoprotein(a), LDL and total cholesterol concentrations between regimens. Plasma high-density lipoprotein (HDL) cholesterol and triglyceride concentrations increased throughout the study only in patients treated with oral estrogen. Conclusions: These data demonstrate that hormone replacement therapy reduces the concentration of lipoprotein(a) when given both orally and transdermally. The lowering effect is achieved quickly because the maximal effect is observed after 3 months of therapy.

AB - Objective: Our purpose was to compare the effect of oral and transdermal hormone replacement therapy on lipoprotein(a) and other plasma lipids in healthy postmenopausal women. Design: A total of 120 postmenopausal women were enrolled in a prospective randomized controlled study, and allocated either to transdermal 17β-estradiol (50 μg/day) or to oral conjugated estrogen (0.625 mg/day). Forty-one age-matched women were used as the reference group. Plasma lipids and lipoproteins were determined every 3 months and differences were sought by statistical analysis. Results: Plasma lipoprotein(a) dropped after 3 months of treatment either with transdermal estradiol (p <0.01) or oral estrogen (p <0.01). Lipoprotein(a) was reduced by 12% and 22%, respectively. No further decreases were seen later on. Plasma total and low-density lipoprotein (LDL) cholesterol concentrations were decreased significantly with both treatments after 3 months of therapy. No difference was seen in the lowering effect on lipoprotein(a), LDL and total cholesterol concentrations between regimens. Plasma high-density lipoprotein (HDL) cholesterol and triglyceride concentrations increased throughout the study only in patients treated with oral estrogen. Conclusions: These data demonstrate that hormone replacement therapy reduces the concentration of lipoprotein(a) when given both orally and transdermally. The lowering effect is achieved quickly because the maximal effect is observed after 3 months of therapy.

KW - Estrogen

KW - HRT

KW - Lipids

KW - Lipoprotein(a)

UR - http://www.scopus.com/inward/record.url?scp=0031686962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031686962&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 157

EP - 162

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 3

ER -